Bruton tyrosine kinase covalent inhibition shapes the immune microenvironment in chronic lymphocytic leukemia

Bruton tyrosine kinase covalent inhibition shapes the immune microenvironment in chronic lymphocytic leukemia

Continuous treatment with ibrutinib not only exerts tumor control but also enhances T cell function in patients with chronic lymphocytic leukemia (CLL). We conducted longitudinal multi-omics analyses in samples from CLL patients receiving ibrutinib upfront to identify potential adaptive mechanisms...

Full description

Saved in:
Bibliographic Details
Main Authors: Daniel Medina-Gil, Laura Palomo, Víctor Navarro, Gonzalo Lázaro, Beatriz Martín-Mur, Cristina Hernández, Oriol Castells, Belén Sánchez, Pau Marc Muñoz-Torres, Carlota Pagès, Gemma Pujadas, Anna Esteve-Codina, Alba Cabirta, Christelle Ferrà, Miguel Alcoceba, Maria José Terol, Rafael Andreu, Mercè Martí, Pau Abrisqueta, Francesc Bosch, Marta Crespo, Spanish Group of Chronic Lymphocytic Leukemia - GELLC
Format: Article
Language:English
Published: Ferrata Storti Foundation 2025-03-01
Series:Haematologica
Online Access:https://haematologica.org/article/view/11975
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://haematologica.org/article/view/11975

Similar Items